Phase 2 Study of BPC 157 Injection for Faster Recovery from Acute Grade II Hamstring Muscle Strain with MRI Confirmation

What this Trial Is About

Researchers are investigating whether pentadecapeptide BPC 157, an experimental peptide, can speed up healing and recovery after an acute grade II hamstring muscle strain. This randomized, double-blind, placebo-controlled Phase 2 study focuses on athletes with MRI-confirmed moderate hamstring injuries, aiming to assess the time it takes to return to unrestricted sport and changes in injury volume using MRI. The study addresses a common sports injury that often leads to extended downtime and risk of re-injury. Participants will be randomly assigned to receive either a daily subcutaneous injection of BPC 157 or a matching placebo for 14 days, alongside a standardized rehabilitation program guided by study physiotherapists. This treatment phase is followed by clinical assessments at Days 3, 7, 14, 28, and 56. After returning to play, participants will be monitored for recurrence over a 3-month period. Safety checks including adverse event monitoring, vital signs, and laboratory tests will be conducted throughout the study. During the trial, participants will undergo MRI scans to measure injury volume and complete pain and functional assessments. Researchers will track hamstring strength and recovery progress using standardized scales and dynamometry. Follow-up visits ensure ongoing safety and monitor for any injury recurrence. The total study duration for each participant includes the 14-day treatment, follow-up visits up to 56 days, and a 3-month observation period after returning to sport.

BPC 157 for Acute Hamstring Muscle Strain Repair